Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dostarlimab - GSK

Drug Profile

Dostarlimab - GSK

Alternative Names: ANB 011; Dostarlimab-gxly; GSK-4057190; JEMPERLI; Jemperli; TSR 042; WBP 285

Latest Information Update: 10 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AnaptysBio
  • Developer GSK; Italian Sarcoma Group
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Endometrial cancer; Solid tumours
  • Phase III Colorectal cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Squamous cell cancer
  • Phase II/III Non-small cell lung cancer
  • Phase II Breast cancer; Cervical cancer; Clear cell sarcoma; Liver cancer; Malignant melanoma; Neuroendocrine tumours; Pancreatic cancer; Rectal cancer; Small cell lung cancer

Most Recent Events

  • 03 Jun 2024 Efficacy data from a phase II trial in Solid tumors by GSK
  • 24 May 2024 Phase-III clinical trials in Squamous cell cancer (Inoperable/Unresectable) (IV) (GSK pipeline, May 2024)
  • 07 May 2024 Phase-II clinical trials in Endometrial cancer (Combination therapy, Recurrent, Late-stage disease) in Japan (IV) (NCT06317311)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top